-
Product Insights
Relapsing Multiple Sclerosis (RMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsing Multiple Sclerosis (RMS) - Drugs In Development, 2023’, provides an overview of the Relapsing Multiple Sclerosis (RMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsing Multiple Sclerosis (RMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Progressive Multiple Sclerosis (PPMS) - Drugs In Development, 2023’, provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewNet Present Value Model: Eisai Co Ltd’s E-2814
Empower your strategies with our Net Present Value Model: Eisai Co Ltd's E-2814 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Pembrolizumab+Vibostolimab) in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Pembrolizumab+Vibostolimab) in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Pembrolizumab+Vibostolimab) in Non Muscle Invasive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GRANITE-001 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GRANITE-001 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GRANITE-001 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: GRANITE-001...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XEN-1101 in Tonic-Clonic (Grand Mal) Seizure
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XEN-1101 in Tonic-Clonic (Grand Mal) Seizure Drug Details: XEN-1101 (1OP-2198) is under development for the...
-
Sector Analysis
Multiple Sclerosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030
Multiple Sclerosis Market Report Overview The drug sales for MS across the 7MM was $18.9 billion in 2020 and will achieve a CAGR of more than 4% during 2020-2030. An increase in the treatment rate of progressive MS, which will mitigate the effect of generic erosion of the top-selling agents will drive market growth during the forecast period. Multiple Sclerosis Market Outlook, 2020-2030 ($ Billion) Buy the Full Report to Gain More Information on the Multiple Sclerosis Market Forecast Download...
-
Product Insights
Wounds Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
A wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of diseases, such as leg ulcers or carcinomas. The Wounds pipeline drugs market research report provides comprehensive information on the therapeutics under development...
-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Net Present Value Model: CNMAU-8
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CNMAU-8 Drug Details CNMAU-8 is under...